Financial Ratios GE HealthCare Technologies Inc.
Equities
GEHC
US36266G1076
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.56 USD | +0.93% |
|
-6.65% | -2.91% |
| 16/01 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
| 16/01 | Sector Update: Health Care | MT |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | - | 6.91 | 5.88 | 5.86 | 5.77 | |
Return on Total Capital | - | 10.93 | 8.9 | 9.93 | 10.75 | |
Return On Equity % | - | 14.28 | 14.72 | 19.15 | 25.69 | |
Return on Common Equity | - | 14.21 | 14.59 | 16.85 | 25.59 | |
Margin Analysis | ||||||
Gross Profit Margin % | 39.43 | 40.8 | 39.14 | 40.52 | 41.71 | |
SG&A Margin | 18.88 | 20.27 | 19.74 | 19.98 | 19.66 | |
EBITDA Margin % | 19.49 | 19.44 | 17.26 | 17.5 | 18.33 | |
EBITA Margin % | 18.2 | 18.16 | 16.01 | 16.23 | 16.97 | |
EBIT Margin % | 15.82 | 15.89 | 13.81 | 14.38 | 15.38 | |
Income From Continuing Operations Margin % | 11.99 | 12.94 | 10.63 | 8.28 | 10.42 | |
Net Income Margin % | 80.67 | 12.78 | 10.45 | 7.08 | 10.13 | |
Net Avail. For Common Margin % | 11.69 | 12.68 | 10.35 | 7.1 | 10.13 | |
Normalized Net Income Margin | 9.57 | 9.96 | 8.28 | 6.32 | 7.85 | |
Levered Free Cash Flow Margin | - | 4.43 | 10.04 | 12.96 | 9.48 | |
Unlevered Free Cash Flow Margin | - | 4.57 | 10.33 | 14.57 | 10.95 | |
Asset Turnover | ||||||
Asset Turnover | - | 0.7 | 0.68 | 0.65 | 0.6 | |
Fixed Assets Turnover | - | 7.93 | 8.06 | 8.12 | 7.79 | |
Receivables Turnover (Average Receivables) | - | 5.85 | 5.27 | 5.25 | 5.1 | |
Inventory Turnover (Average Inventory) | - | 5.88 | 5.44 | 5.65 | 5.88 | |
Short Term Liquidity | ||||||
Current Ratio | 0.9 | 1.04 | 1.16 | 1.05 | 1.04 | |
Quick Ratio | 0.52 | 0.62 | 0.74 | 0.74 | 0.75 | |
Operating Cash Flow to Current Liabilities | 0.26 | 0.24 | 0.29 | 0.23 | 0.2 | |
Days Sales Outstanding (Average Receivables) | - | 62.42 | 69.24 | 69.5 | 71.7 | |
Days Outstanding Inventory (Average Inventory) | - | 62.05 | 67.05 | 64.57 | 62.22 | |
Average Days Payable Outstanding | - | 79.73 | 88.02 | 94.02 | 95.43 | |
Cash Conversion Cycle (Average Days) | - | 44.75 | 48.28 | 40.06 | 38.49 | |
Long Term Solvency | ||||||
Total Debt/Equity | 0.23 | 0.22 | 90.02 | 134.92 | 108.37 | |
Total Debt / Total Capital | 0.23 | 0.22 | 47.37 | 57.43 | 52.01 | |
LT Debt/Equity | 0.21 | 0.18 | 88.78 | 119.66 | 89.68 | |
Long-Term Debt / Total Capital | 0.21 | 0.18 | 46.72 | 50.93 | 43.04 | |
Total Liabilities / Total Assets | 38.2 | 35.78 | 65.17 | 77.48 | 73.85 | |
EBIT / Interest Expense | 41.15 | 69.85 | 29.44 | 5.57 | 6.54 | |
EBITDA / Interest Expense | 50.7 | 85.48 | 39.33 | 7.23 | 8.35 | |
(EBITDA - Capex) / Interest Expense | 47.11 | 79.42 | 35.72 | 6.46 | 7.48 | |
Total Debt / EBITDA | 0.01 | 0.01 | 2.55 | 2.7 | 2.43 | |
Net Debt / EBITDA | -0.29 | -0.15 | 2.13 | 2.02 | 1.68 | |
Total Debt / (EBITDA - Capex) | 0.01 | 0.01 | 2.81 | 3.02 | 2.71 | |
Net Debt / (EBITDA - Capex) | -0.31 | -0.16 | 2.34 | 2.26 | 1.88 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | 3.19 | 2.45 | 4.3 | 6.6 | 0.61 | |
Gross Profit, 1 Yr. Growth % | 3.34 | 6.01 | 0.07 | 10.35 | 3.57 | |
EBITDA, 1 Yr. Growth % | 20.58 | 2.18 | -7.43 | 10.35 | 5.41 | |
EBITA, 1 Yr. Growth % | 22.51 | 2.24 | -8.05 | 10.48 | 5.2 | |
EBIT, 1 Yr. Growth % | 28.36 | 2.87 | -9.38 | 13.94 | 7.65 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 22.43 | 10.54 | -14.33 | -16.98 | 26.7 | |
Net Income, 1 Yr. Growth % | 808.53 | -83.77 | -14.73 | -27.71 | 43.9 | |
Normalized Net Income, 1 Yr. Growth % | 28.55 | 6.58 | -13.24 | -16.39 | 24.99 | |
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | - | -27.27 | 42.76 | |
Accounts Receivable, 1 Yr. Growth % | - | 55.41 | 7.48 | 6.55 | 0.68 | |
Inventory, 1 Yr. Growth % | - | 22.08 | 10.74 | -9.05 | -1.07 | |
Net Property, Plant and Equip., 1 Yr. Growth % | - | 1.5 | 3.53 | 8.04 | 2 | |
Total Assets, 1 Yr. Growth % | - | 8.59 | 4.68 | 17.85 | 1.96 | |
Tangible Book Value, 1 Yr. Growth % | - | 52.55 | -359.71 | 41.8 | -18.25 | |
Common Equity, 1 Yr. Growth % | - | 13.09 | -43.82 | -23.77 | 18.41 | |
Cash From Operations, 1 Yr. Growth % | -15.18 | -4.74 | 31.49 | -0.57 | -7.14 | |
Capital Expenditures, 1 Yr. Growth % | -9.89 | 2.11 | 28.1 | 24.84 | 3.62 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | 173.82 | 35.68 | -26.38 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | 171.71 | 48.31 | -24.38 | |
Dividend Per Share, 1 Yr. Growth % | - | - | - | - | 4.17 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | 2.82 | 3.37 | 5.44 | 3.56 | |
Gross Profit, 2 Yr. CAGR % | - | 4.67 | 3 | 5.08 | 6.91 | |
EBITDA, 2 Yr. CAGR % | - | 11 | -2.74 | 0.03 | 7.85 | |
EBITA, 2 Yr. CAGR % | - | 11.92 | -3.04 | -0.33 | 7.81 | |
EBIT, 2 Yr. CAGR % | - | 14.91 | -3.45 | 0.3 | 10.75 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 16.33 | -2.68 | -15.67 | 2.56 | |
Net Income, 2 Yr. CAGR % | - | 21.43 | -62.8 | -21.49 | 1.99 | |
Normalized Net Income, 2 Yr. CAGR % | - | 17.05 | -3.84 | -15.98 | 2.22 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | - | -21.31 | 1.9 | |
Accounts Receivable, 2 Yr. CAGR % | - | - | 23.72 | 7.01 | 3.57 | |
Inventory, 2 Yr. CAGR % | - | - | 16.27 | 0.36 | -5.14 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 2.51 | 5.76 | 4.98 | |
Total Assets, 2 Yr. CAGR % | - | - | 6.61 | 11.07 | 9.61 | |
Tangible Book Value, 2 Yr. CAGR % | - | - | 99.04 | 91.9 | 7.66 | |
Common Equity, 2 Yr. CAGR % | - | - | -20.29 | -34.56 | -4.99 | |
Cash From Operations, 2 Yr. CAGR % | - | -10.11 | 11.92 | 14.34 | -3.91 | |
Capital Expenditures, 2 Yr. CAGR % | - | -4.08 | 14.37 | 24.92 | 13.73 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 84 | -0.06 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 91.94 | 5.9 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | 3.31 | 4.44 | 3.81 | |
Gross Profit, 3 Yr. CAGR % | - | - | 3.11 | 5.39 | 4.58 | |
EBITDA, 3 Yr. CAGR % | - | - | 4.48 | 0.74 | 1.79 | |
EBITA, 3 Yr. CAGR % | - | - | 4.82 | 0.52 | 1.48 | |
EBIT, 3 Yr. CAGR % | - | - | 6.17 | 1.15 | 2.69 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 5.05 | -7.71 | -3.41 | |
Net Income, 3 Yr. CAGR % | - | - | 7.93 | -53.58 | -3.92 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 5.93 | -9.05 | -4.09 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | - | -4.03 | |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | 17.71 | 4.86 | |
Inventory, 3 Yr. CAGR % | - | - | - | 7.13 | -0.12 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | 4.32 | 4.49 | |
Total Assets, 3 Yr. CAGR % | - | - | - | 10.23 | 7.94 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 77.77 | 44.39 | |
Common Equity, 3 Yr. CAGR % | - | - | - | -21.47 | -20.26 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 2.04 | 7.59 | 6.68 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | 5.63 | 17.76 | 17.37 | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 35.58 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 40.71 | |
Compound Annual Growth Rate Over Five Years | ||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | 3.41 | |
Gross Profit, 5 Yr. CAGR % | - | - | - | - | 4.62 | |
EBITDA, 5 Yr. CAGR % | - | - | - | - | 5.38 | |
EBITA, 5 Yr. CAGR % | - | - | - | - | 5.53 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | 7.42 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 4.05 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | 5.51 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 3.87 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | -0.39 | |
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | 8.8 |
- Stock Market
- Equities
- GEHC Stock
- Financials GE HealthCare Technologies Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















